Parker Institute for Cancer Immunotherapy
Overview
Parker Institute for Cancer Immunotherapy is a non-profit research organization and investor that funds and supports cancer immunotherapy research and invests in biotech startup companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Dispatch Biotherapeutics | Jul 2025 | Series A | Lead |
| ArsenalBio | Sep 2024 | Series C | Co-investor |
| Xaira Therapeutics | Apr 2024 | Series A | Co-investor |
| Georgiamune | Aug 2023 | Series A | Lead |
| Akamis Bio | Jan 2023 | Convertible Debt | Lead |
For institutional investors. Book with your work email.
Key People
Ansuman Satpathy
Co Director
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Parker Institute for Cancer Immunotherapy based?
Parker Institute for Cancer Immunotherapy is headquartered in San Francisco, California, United States.
When was Parker Institute for Cancer Immunotherapy founded?
Parker Institute for Cancer Immunotherapy was founded in 2015.
How many portfolio companies does Parker Institute for Cancer Immunotherapy have?
Parker Institute for Cancer Immunotherapy has 10 portfolio companies in Caplight's dataset.
What are some companies in Parker Institute for Cancer Immunotherapy's portfolio?
Recent investments visible on Caplight include Dispatch Biotherapeutics, ArsenalBio, Xaira Therapeutics, Georgiamune, Akamis Bio.
What was Parker Institute for Cancer Immunotherapy's most recent investment?
Parker Institute for Cancer Immunotherapy's most recent investment on Caplight was in Dispatch Biotherapeutics in 2025.
What sectors does Parker Institute for Cancer Immunotherapy focus on?
Parker Institute for Cancer Immunotherapy focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Parker Institute for Cancer Immunotherapy focus on?
Parker Institute for Cancer Immunotherapy typically invests at the Early stage.
What is Parker Institute for Cancer Immunotherapy's AUM?
Parker Institute for Cancer Immunotherapy's assets under management are estimated between $250.0M and $500.0M.